Evidence map›Paper›PMID 39092860›Full record

ArticleAnnals of medicine2024

Comparison of two platinum-containing chemotherapy regimens in the treatment of advanced cervical cancer with concurrent chemoradiotherapy.

Ya-Yi Chen, Yi-Tong Huang

Abstract readComparative Study
In one paragraph

Article in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Polymer Nanoparticles Advancements for Gynecological Cancers.International journal of nanomedicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ya-Yi ChenDepartment of Gynecology and Oncology, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China.
Yi-Tong HuangDepartment of Gynecology and Oncology, The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe present study aims to compare the efficacy and side effects of a platinum-containing combination regimen and platinum single-drug concurrent chemoradiotherapy (CCRT) in patients with advanced cervical cancer (CC) and to understand the prognostic factors in patients with CC.

methodsA total of 108 cases of CC treated in Wenzhou Central Hospital were retrospectively selected. Patients in the monotherapy (single-drug) group received external pelvic radiotherapy (RT) and platinum-based single-drug chemotherapy (CT). Patients in the combined group received external pelvic RT and platinum-containing CT. The efficacy, CCRT time, 3-year survival rate after treatment and side effects were compared between the two groups, and the prognostic factors were analysed.

resultsThe total effective rate was 74.07% in the monotherapy group and 72.22% in the combined group (

conclusionThe efficacy of the two regimens in the treatment of advanced CC was similar. However, the side effects increased significantly during combined treatment. PROGNOSTIC FACTORS: A higher patient age, having an AC and stage of IIIa and a high SCC-Ag value before treatment resulted in a relatively low survival rate.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyUterine Cervical NeoplasmsAdultAgedAntigens, NeoplasmCisplatinFemaleHumansMiddle AgedOrganoplatinum CompoundsPrognosisRetrospective StudiesSerpinsSurvival RateTreatment OutcomeAntigens, NeoplasmCisplatinOrganoplatinum CompoundsSerpinssquamous cell carcinoma-related antigenCervical cancerconcurrent chemotherapy and radiotherapy, combined regimen chemotherapyprognosissingle-drug chemotherapy

Identifiers

PMID39092860
PMCPMC11299448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.